Transdermal Co-Delivery of Sumatriptan Succinate and Naproxen Sodium via Dissolving Microneedle Patch

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Azka Yousaf, Zulcaif Ahmad, Asif Mahmood, Muhammad Imran Khan, Muhammad Furqan Akhtar
{"title":"Transdermal Co-Delivery of Sumatriptan Succinate and Naproxen Sodium via Dissolving Microneedle Patch","authors":"Azka Yousaf,&nbsp;Zulcaif Ahmad,&nbsp;Asif Mahmood,&nbsp;Muhammad Imran Khan,&nbsp;Muhammad Furqan Akhtar","doi":"10.1007/s12247-025-10007-6","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Current migraine therapies face challenges such as poor patient compliance and delayed onset of action, necessitating novel delivery strategies. The development of transdermal drug delivery systems, particularly microneedle patches, offered a viable substitute for enhancing patient compliance and avoiding the first-pass effect.</p><h3>Method</h3><p>This research focused on the fabrication and characterization of a microneedle patch to deliver the combination of sumatriptan succinate and naproxen sodium. Microneedles were fabricated using Polyvinyl alcohol and Hydroxy propyl methyl cellulose via solvent casting technique. The prepared microneedle patches were characterized for their morphological and mechanical properties, drug release kinetics, drug content determination, and ability of the microneedles to penetrate.</p><h3>Result</h3><p>SEM analysis confirmed the uniformity in the height of the microneedles with an average height of 500 µm and a base diameter of 200 µm. The microneedle patches showed adequate mechanical strength to pierce the stratum corneum without breaking, and an average insertion force of about 5.28 ± 0.1 N was needed. <i>In-vitro</i> insertion and irritation study verified the successful insertion of needles without any notable deformation and no irritation to the skin was observed. XRD study confirms the crystalline structure of both API individually and the amorphous state in the formulation. <i>In-vitro</i> release experiments revealed a regulated release profile over 24 h i.e. 86.8% ± 0.3% (Sumatriptan succinate) and 86.34% ± 0.7% (Naproxen sodium). The drug loading efficiency of both drugs i.e. Sumatriptan succinate and Naproxen sodium was observed as 100% and 99.7% respectively.</p><h3>Conclusion</h3><p>This innovative approach could improve patient compliance and outcomes compared to conventional therapies. More animal studies should be done to ascertain the effectiveness and safety of the system on a commercial scale.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"20 3","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12247-025-10007-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

Current migraine therapies face challenges such as poor patient compliance and delayed onset of action, necessitating novel delivery strategies. The development of transdermal drug delivery systems, particularly microneedle patches, offered a viable substitute for enhancing patient compliance and avoiding the first-pass effect.

Method

This research focused on the fabrication and characterization of a microneedle patch to deliver the combination of sumatriptan succinate and naproxen sodium. Microneedles were fabricated using Polyvinyl alcohol and Hydroxy propyl methyl cellulose via solvent casting technique. The prepared microneedle patches were characterized for their morphological and mechanical properties, drug release kinetics, drug content determination, and ability of the microneedles to penetrate.

Result

SEM analysis confirmed the uniformity in the height of the microneedles with an average height of 500 µm and a base diameter of 200 µm. The microneedle patches showed adequate mechanical strength to pierce the stratum corneum without breaking, and an average insertion force of about 5.28 ± 0.1 N was needed. In-vitro insertion and irritation study verified the successful insertion of needles without any notable deformation and no irritation to the skin was observed. XRD study confirms the crystalline structure of both API individually and the amorphous state in the formulation. In-vitro release experiments revealed a regulated release profile over 24 h i.e. 86.8% ± 0.3% (Sumatriptan succinate) and 86.34% ± 0.7% (Naproxen sodium). The drug loading efficiency of both drugs i.e. Sumatriptan succinate and Naproxen sodium was observed as 100% and 99.7% respectively.

Conclusion

This innovative approach could improve patient compliance and outcomes compared to conventional therapies. More animal studies should be done to ascertain the effectiveness and safety of the system on a commercial scale.

琥珀酸舒马匹坦与萘普生钠溶微针贴剂经皮共给药研究
目前的偏头痛治疗面临着诸如患者依从性差和行动延迟等挑战,需要新的交付策略。透皮给药系统的发展,特别是微针贴片,为提高患者依从性和避免首过效应提供了可行的替代方案。方法研究琥珀酸舒马普坦与萘普生钠联合递送的微针贴片的制备与表征。以聚乙烯醇和羟丙基甲基纤维素为原料,采用溶剂铸造工艺制备了微针。对制备的微针贴片进行了形态学、力学性能、药物释放动力学、药物含量测定和微针穿透能力的表征。结果sem分析证实了微针高度的均匀性,平均高度为500µm,基径为200µm。微针贴片具有足够的机械强度,可穿透角质层而不破裂,平均插入力约为5.28±0.1 N。体外插入和刺激研究证实针头插入成功,没有任何明显的变形,也没有观察到皮肤刺激。XRD研究证实了原料药的单晶结构和配方中的非晶态。体外释放实验结果显示,24 h内舒马普坦(琥珀酸舒马普坦)和萘普生钠(萘普生钠)的释放量分别为86.8%±0.3%和86.34%±0.7%。琥珀酸舒马普坦和萘普生钠的载药率分别为100%和99.7%。结论与传统治疗方法相比,该创新方法可提高患者的依从性和预后。应该进行更多的动物研究,以确定该系统在商业规模上的有效性和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信